RAPP
NASDAQRapport Therapeutics Inc.
News25/Ratings12
News · 26 weeks61+200%
2026-03-012026-08-23
Mix2890d
- Insider15(54%)
- SEC Filings6(21%)
- Other5(18%)
- Analyst2(7%)
Latest news
25 items- PRRapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical ProgramBOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here. The event will feature leading experts in bipolar disorder Mauricio Tohen, MD, DrPH, MBA (University of New Mexico Health Science Center), and Gary Sachs, MD (Massachusetts General Hospital, Harvard Medical School), who will
- INSIDERChief Development Officer Yeleswaram Krishnaswamy sold $20,160 worth of shares (404 units at $49.90) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 246,022 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
- INSIDERChief Executive Officer Ceesay Abraham sold $2,433,176 worth of shares (51,499 units at $47.25) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 486,108 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rapport Therapeutics Inc.SCHEDULE 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 10-Q filed by Rapport Therapeutics Inc.10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECRapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- PRRapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business UpdateRAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or th
- INSIDERChief Executive Officer Ceesay Abraham sold $93,061 worth of shares (2,210 units at $42.11) as part of a pre-agreed trading plan, decreasing direct ownership by 0.41% to 537,607 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- ANALYSTWilliam Blair initiated coverage on Rapport TherapeuticsWilliam Blair initiated coverage of Rapport Therapeutics with a rating of Outperform
- INSIDERChief Executive Officer Ceesay Abraham sold $328,437 worth of shares (8,210 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 539,817 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERChief Operating Officer Gault Cheryl sold $415,798 worth of shares (10,000 units at $41.58) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 149,914 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERChief Executive Officer Ceesay Abraham sold $327,398 worth of shares (8,220 units at $39.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 548,027 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- ANALYSTLeerink Partners initiated coverage on Rapport Therapeutics with a new price targetLeerink Partners initiated coverage of Rapport Therapeutics with a rating of Outperform and set a new price target of $52.00
- INSIDERSEC Form 4 filed by Director Maraganore John4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Perez Robert J4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Paul Steven M4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Silva Paul M4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Healy James4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Huber Reid M4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Young Wendy B.4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Director Sanchez Ramiro4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
RAPP FAQ
6 questionsWhere does RAPP stock trade?
Rapport Therapeutics Inc. (RAPP) is listed on NASDAQ.What sector and industry is RAPP in?
Rapport Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rapport Therapeutics Inc. go public?
Rapport Therapeutics Inc. (RAPP) completed its IPO in 2024.What are analysts saying about RAPP?
Rapport Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-07-28. Recent price targets range from $3100.00 to $4700.00.What companies are similar to RAPP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RAPP side-by-side with any of them on Quantisnow.How can I track RAPP on Quantisnow?
Quantisnow aggregates Rapport Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RAPP to receive live email and push alerts on every new disclosure.